The reinstatement of a Market Perform rating by Raymond James suggests a neutral outlook on ACADIA Pharmaceuticals' stock. This indicates that the analyst does not expect significant outperformance or underperformance relative to the market. As such, the short-term impact on the stock price is likely neutral.